Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging.

Raghava Kashyap, Michael S. Hofman, Michael Michael, Grace Kong, Timothy Akhurst, Peter Eu, Diana Zannino, Rodney J. Hicks, Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 42, pp. 176- 185 ,(2015) , 10.1007/S00259-014-2906-4

T. Binderup, U. Knigge, A. Loft, B. Federspiel, A. Kjaer, 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors Clinical Cancer Research. ,vol. 16, pp. 978- 985 ,(2010) , 10.1158/1078-0432.CCR-09-1759

Irvin M Modlin, Kjell Oberg, Daniel C Chung, Robert T Jensen, Wouter W de Herder, Rajesh V Thakker, Martyn Caplin, Gianfranco Delle Fave, Greg A Kaltsas, Eric P Krenning, Steven F Moss, Ola Nilsson, Guido Rindi, Ramon Salazar, Philippe Ruszniewski, Anders Sundin, Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology. ,vol. 9, pp. 61- 72 ,(2008) , 10.1016/S1470-2045(07)70410-2

Stefano Severi, Oriana Nanni, Lisa Bodei, Maddalena Sansovini, Annarita Ianniello, Stefania Nicoletti, Emanuela Scarpi, Federica Matteucci, Laura Gilardi, Giovanni Paganelli, Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 40, pp. 881- 888 ,(2013) , 10.1007/S00259-013-2369-Z

H. Bahri, L. Laurence, J. Edeline, H. Leghzali, A. Devillers, J.-L. Raoul, M. Cuggia, H. Mesbah, B. Clement, E. Boucher, E. Garin, High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation The Journal of Nuclear Medicine. ,vol. 55, pp. 1786- 1790 ,(2014) , 10.2967/JNUMED.114.144386

Julie Nonnekens, Melissa van Kranenburg, Cecile E.M.T. Beerens, Mustafa Suker, Michael Doukas, Casper H.J. van Eijck, Marion de Jong, Dik C. van Gent, Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib. Theranostics. ,vol. 6, pp. 1821- 1832 ,(2016) , 10.7150/THNO.15311

Jonathan Strosberg, Ghassan El-Haddad, Edward Wolin, Andrew Hendifar, James Yao, Beth Chasen, Erik Mittra, Pamela L. Kunz, Matthew H. Kulke, Heather Jacene, David Bushnell, Thomas M. O’Dorisio, Richard P. Baum, Harshad R. Kulkarni, Martyn Caplin, Rachida Lebtahi, Timothy Hobday, Ebrahim Delpassand, Eric Van Cutsem, Al Benson, Rajaventhan Srirajaskanthan, Marianne Pavel, Jaime Mora, Jordan Berlin, Enrique Grande, Nicholas Reed, Ettore Seregni, Kjell Öberg, Maribel Lopera Sierra, Paola Santoro, Thomas Thevenet, Jack L. Erion, Philippe Ruszniewski, Dik Kwekkeboom, Eric Krenning, Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors The New England Journal of Medicine. ,vol. 376, pp. 125- 135 ,(2017) , 10.1056/NEJMOA1607427

Stefano Severi, Ilaria Grassi, Silvia Nicolini, Maddalena Sansovini, Alberto Bongiovanni, Giovanni Paganelli, Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. OncoTargets and Therapy. ,vol. 10, pp. 551- 557 ,(2017) , 10.2147/OTT.S97584

David LH Chan, Nick Pavlakis, Geoffrey P Schembri, Elizabeth J Bernard, Edward Hsiao, Aimee Hayes, Tristan Barnes, Connie Diakos, Mustafa Khasraw, Jaswinder Samra, Enid Eslick, Paul J Roach, Alexander Engel, Stephen J Clarke, Dale L Bailey, Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. Theranostics. ,vol. 7, pp. 1149- 1158 ,(2017) , 10.7150/THNO.18068

Deborah Pencharz, Gopinath Gnanasegaran, Shaunak Navalkissoor, Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy. British Journal of Radiology. ,vol. 91, pp. 20180108- ,(2018) , 10.1259/BJR.20180108